AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...
AZN Lawsuit Alert! Class Action Against AstraZeneca Plc.
A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...
News Medical12h
Researchers uncover cause of persistent blood clots despite treatment
A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...
AstraZeneca PLC ADR outperforms competitors on strong trading day
The AstraZeneca PLC ADR AZN rose 2.34% to $74.43 Wednesday, on what proved to be an all-around mixed trading session for the ...
News Medical3d
Single dose of antibody shields macaques from severe H5N1 influenza
National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...